Dissolution of SNS Growth Hormone Advisory Committee 2026: what changes

Key data

The supervision framework for growth hormone treatments financed by the National Health System changes effectively as of April 17, 2026. The Resolution from the General Directorate of Common Services Portfolio of the SNS and Pharmacy declares extinct the Advisory Committee for growth hormone and related substances, the advisory body that until now supervised the prescription and follow-up of these treatments within the SNS.

The measure responds, according to the resolution itself, to an internal administrative reorganization of the Ministry of Health. However, the regulation does not specify which body or concrete structure will assume the functions that the dissolved committee was exercising, which generates operational uncertainty for the healthcare professionals involved.

What does this regulation establish?

The resolution has a single and concrete purpose: to declare extinct the Advisory Committee for growth hormone and related substances. This committee had assigned advisory functions on two main areas:

• The prescription of growth hormone treatments financed by the SNS.
• The follow-up and supervision of such treatments in patients with active therapies.

By becoming extinct, these functions must be assumed by other bodies or structures of the healthcare system. The resolution does not expressly designate any successor, which implies that the assignment of responsibilities will remain pending further development by the Ministry of Health or by the autonomous communities in the exercise of their healthcare competencies.

The extinction is retroactive to the date of the resolution (April 17, 2026), although its publication in the BOE occurred on April 29, 2026, twelve days later.

Operational impact and practical consequences

Although this resolution does not entail direct economic costs for companies or individuals, it does have relevant operational consequences for healthcare professionals and affected patients:

• Temporary supervision gap: Until a successor body is designated, there is no formal committee to advise on growth hormone prescription in the SNS. This can generate uncertainty in clinical decision-making that previously required the committee's approval or consultation.
• Continuity of active treatments: Patients with ongoing therapies do not see their medication interrupted by this resolution, but the supervised follow-up framework changes. Healthcare professionals must verify with their centers and health authorities how this follow-up is now managed.
• Administrative reorganization: The Ministry of Health will have to articulate, presumably through a subsequent resolution or instruction, which structure assumes the competencies of the dissolved committee.

Who does it affect?

• SNS healthcare professionals who prescribe growth hormone treatments and related substances, and who until now operated under the supervision framework of the extinct committee.
• Patients with active treatments of growth hormone financed by the SNS, whose clinical follow-up was linked to the supervision framework of the committee.
• Healthcare managers and directors of SNS hospitals and centers who must adapt their internal protocols for prescription and follow-up.
• Autonomous communities with competencies in healthcare management, which may be called upon to assume or reorganize supervision functions in this area.

Practical example

An endocrinologist at a public hospital who has pediatric patients with growth hormone deficiency in treatment financed by the SNS was following a prescription and periodic review protocol that included, in certain cases, consultation or notification to the Advisory Committee.

As of April 17, 2026, that committee no longer exists. If the protocol of their hospital or autonomous community made express reference to the committee as a supervision body, that protocol becomes outdated. The professional must consult with the medical direction of their center to learn the interim procedure applicable until the Ministry of Health or the corresponding autonomous community designates the successor body.

The patients of that endocrinologist do not see their prescription altered, but the doctor does not have a formal advisory body to turn to in case of doubt about the suitability or continuity of treatment under SNS criteria.

What should healthcare professionals do now?

1. Review internal protocols for growth hormone prescription at their healthcare center to identify if they reference the extinct Advisory Committee and update those references.
2. Consult with the medical direction or management of the center to learn the interim procedure applicable while the Ministry of Health does not designate a successor body.
3. Verify with the corresponding autonomous community if there are instructions or circulars that regulate the supervision of these treatments at the autonomous level, given that healthcare competencies are transferred.
4. Maintain the usual clinical follow-up of patients with active treatments, as the extinction of the committee does not suspend or modify the clinical obligations of the healthcare professional.
5. Stay alert to subsequent resolutions or instructions from the Ministry of Health that designate the body that will assume the functions of the dissolved committee.